Evaluation of Thrombocytopenia Associated with Enormous use of Proton Pump Inhibitors

Ansar Raza Mohsin, Umair Hayat Khan, Bilal Akbar


Objective: The main aim of this study was evaluate the thrombocytopenia associated with enormous use of proton pump inhibitors (PPI).

Place and duration of study: This study was carried out in a duration of 10 months from February 2018 to November 2018 in medical department of Mayo Hospital Lahore.

Materials and Methods: A total of 50 patients were selected who were taking PPI for long term and then their blood samples were taken and sent to a reliable laboratory for CBC and look for thrombocytopenia. All these patients had previous history of NSAID's use and had developed gastric ulcers due to it. Informed consent was taken from all the patients or their relatives. Ethical committee approval was taken. A pre-designed proforma was used to collect the data.

Results: A total of 50 patients were selected to collect the data who were using PPI. A minor decrease in white blood cells were seen in all these patients. All the patients were given one prophylactic dose of heparin which could be the cause of thrombocytopenia. The other drug was proton pump inhibitor and PPI were stopped. 2 days after the PPI were stopped the thrombocyte count increased to 99 × 103 /mm 3. Patients had nonspecific gastritis which was revealed upon upper GI endoscopy. No evidence of H.Pylori infection was seen.

Conclusion: It was concluded that while making the differential diagnosis of thrombocytopenia PPI should be kept in mind.

Keywords: Thrombocytopenia, PPI, inhibitors.

Full Text:



Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18:678–682.

Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751–767.

Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol. 2016;111:1085–1086.

Fujisawa T, Adachi K, Komazawa Y, et al. Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists. Aliment Pharmacol Ther. 2004;20:559–565.

Adachi K, Komazawa Y, Mihara T, et al. Comparative study of the speed of acidsuppressing effects of oral administration of cimetidine and famotidine. J GastroenterolHepatol. 2005;20:1012– 1015.

Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassiumcompetitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-Nmethylmethanamine monofumarate (TAK-438) J Pharmacol Exp Ther. 2011;339:412–420.

Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H + , K + -ATPase. Aliment Pharmacol Ther. 2015;42:1315–1326.

Sakurai Y, Nishimura A, Kennedy G, et al. Safety, Tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.

Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label crossover study. Aliment PharmacolTher. 2015;42:719–730.

Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240–251.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and secondline triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439– 1446.

Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:1385–1391.

Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103:20–26.

Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001;15:1929–1937.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.